Shares of Glenmark Prescribed drugs Ltd had been buying and selling within the inexperienced and 1% larger on 23 October after the corporate introduced that its US affiliate, Glenmark Prescribed drugs Inc., will provide Ropivacaine Hydrochloride Injection USP within the US market.
The drugs might be provided in single-dose vials containing 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL).
Glenmark Prescribed drugs acknowledged that the injection is bioequivalent and therapeutically equal to Naropin injection, which is made by Fresenius Kabi USA LLC.Ropivacaine injections are used to numb particular areas of the physique previous to or throughout surgical procedure or childbirth.
It may also be used to deal with acute or extreme ache. The injection is used as an anesthetic to numb particular elements of the physique previous to or throughout surgical procedure or childbirth, in addition to to alleviate acute discomfort.Glenmark Prescribed drugs Inc. intends to start advertising and marketing of the medication in November 2025.
In response to IQVIA gross sales statistics for the 12-month interval ending August 2025, the Naropin Injection market generated an annual income of roughly $20.9 million.
“This launch represents one other essential addition to Glenmark’s increasing injectable portfolio and reinforces our dedication to deliver high quality and reasonably priced alternate options to marketplace for sufferers in want,” Marc Kikuchi, President and Enterprise Head, North America, mentioned.
Glenmark’s Ropivacaine Hydrochloride Injection is just authorised for the indications specified on the authorised label.
At 12:40 pm, Glenmark Pharma’s shares had been buying and selling at ₹1,856.90, up 0.08% on the NSE.
